ATAI

Business Context and Reporting Period

Company: ATAI Life Sciences N.V. (formerly Atai Beckley N.V.)
Filing Type: Form 8-K (Current Report)
Date of Report: October 20, 2025
Event: Closing of a public offering of common shares and full exercise of the underwriters' option to purchase additional shares.

Key Financial Metrics

Capital Raised: The Company sold a total of 27,283,750 common shares (including 3,558,750 shares from the full exercise of the underwriters' option).
Offering Price: $5.48 per share.
Net Proceeds: The filing text does not provide a clear value for the total net proceeds after underwriting discounts and commissions.
Liquidity Outlook: Management estimates that existing cash, cash equivalents, short-term investments, and the net proceeds from this offering will be sufficient to fund operations into 2029.

Material Changes

This filing represents a significant capital event rather than a periodic financial performance report. The primary material change is the increase in share count and cash liquidity resulting from the closing of the public offering on October 20, 2025.

Guidance, Outlook, and Use of Proceeds

Use of Proceeds: The Company intends to use net proceeds to advance clinical development across its pipeline, specifically:

• Funding the planned Phase 3 clinical program for BPL-003 (mebufotenin benzoate) nasal spray through the top-line data readout of the first Phase 3 trial.
• Completing the Phase 2 clinical trial of VLS-01 (buccal film DMT).
• Completing the Phase 2a study for EMP-01 (oral R-MDMA).
• Working capital and general corporate purposes.

Forward-Looking Statements: The filing includes standard cautionary notes regarding risks and uncertainties that could cause actual results to differ from expectations, referencing the "Risk Factors" in the Company's 2024 Form 10-K.

Investor Verification Checklist

• Verify the exact net proceeds amount by reviewing the accompanying press release (Exhibit 99.1) or the final prospectus, as the 8-K text omits the specific dollar figure.
• Confirm the dilution impact of the 27,283,750 new shares on existing shareholders.
• Review the "Risk Factors" section of the most recent Form 10-K (filed March 17, 2025) for details on clinical trial risks and regulatory hurdles.
• Monitor upcoming clinical trial milestones for BPL-003, VLS-01, and EMP-01 as the primary drivers of future value.